Overview
The purpose of this study is to compare changes in cardiac structure and function, biomarkers, and patient reported outcomes between adults with congenital heart disease (ACHD) randomized to angiotensin receptor-neprilysin inhibitor (ARNI) therapy vs placebo.
Eligibility
Inclusion Criteria:
- Congenital Heart Disease Diagnosis
- Age 18 or Older
Exclusion Criteria:
- Stage IV chronic kidney disease defined as creatinine clearance \<30 ml/min
- Hyperkalemia defined as serum potassium \>5.2 mmol/l,
- Hypotension defined as systolic blood pressure \<100 mmHg,
- History of angioedema related to previous ACE or ARB therapy
- Patients diagnosed with diabetes using Aliskiren,
- Pregnancy.
- Drug Therapies
- Amifostine
- Droperidol
- Dantrolene
- CYP3A4 Inhibitors
- Obinutuzumab
- Aliskiren
- Lithium
- Sparsentan
- ACE inhibitor
- ARB
- ARNI
